Introduction The risk for brain injury manifested as cerebral palsy is higher in very preterm
born children than in term. Prenatal administration of magnesium sulfate (MgSO4) has been …

Children born preterm have an increased risk of severe morbidity, eg cerebral palsy (CP),
compared to children born at term. CP cannot be treated, which is why a prophylactic …

Key content: The prevalence of preterm birth is increasing and owing to advances in
neonatal care, more infants are surviving. However, in parallel with this, the incidence of …

Objective To study the effect of antenatal magnesium sulphate (MgSO4) on cerebral palsy
(CP) in a manner that also provides adequate power for a linked trial sequential analysis …

Cerebral palsy occurs in three to four infants per 1000 live births. Preterm birth prior to 34
weeks' gestation is a major risk factor. Five randomized controlled trials of antenatal …

The aim of our study was to assess the feasibility of implementing a protocol for the use of
magnesium sulfate to prevent cerebral palsy. This retrospective single-center study included …

Background Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …

Background Ordinary meta‐analyses indicate that magnesium sulphate (MgSO4) treatment
in women at imminent risk for preterm delivery decreases the offspring's risk of cerebral …

Prevention of neurologic disability associated with preterm birth is one of the major
challenges in current perinatal medicine. Magnesium sulfate (MgSO4), the focus of this …

Abstract Background: Preterm delivery< 32-week gestation is associated with significant
neurodevelopmental morbidity ranging from mild delay to profound disability. Several …